Choi, “Enhancement of outward potassium current may participate in beta-amyloid peptide-induced cortical neuronal death” Neuron, Vol. Garthwaita, “Excitatory amino acid neurotoxicity and neurodegenerative disease” Trends PharmacolSci, Vol. Olney, “Excitotoxicity and the NMDA receptor-still lethal after eight years” Trends Neurosci, Vol. Lyeth, “Neurotransmitter-mediated mechanisms of traumatic brain injury: acetylcholine and excitatory amino acids” J TraumaSuppl, Vol. Rothman, “The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death” Neurosci, Vol. These results indicate that the nucleotides included in Nucleo CMP Forte ® are promising therapeutic molecules for the prevention of neuronal death in brain caused by focal ischemia, Parkinson’s disease or other neurodegenerative pathologies.ĭ.W. More interestingly, drug pre-treatment significantly reduced MPP +- and glutamate-induced cell death in SH-SY5Y cells and in rat cortical cells. Nucleo CMP Forte ® pre-treatment significantly increased the rate of cell division in SH-SY5Y cells, as well as the synthesis of triglycerides and phospholipids.
Cell viability was measured at different times. We used the human dopaminergic cell line SH-SY5Y and a primary culture of rat cortical cells pre-treated with the drug for 24 hours and then exposed to MPP + or glutamate at a range of concentrations. We examined its neuroprotective effects on cell toxicity induced by glutamate excitotoxicity or by 1-methyl-4-phenyl-pyridinium (MPP +), an in vitro cell model of Parkinson’s disease. Its effects on brain pathologies has re-ceived little attention. It has been prescribed for peripheral nervous system disorders, such as lum-bosciatalgia, diabetic or alcoholic polyneuropathy, or trigeminal neuralgia. Nucleo CMP Forte ® is a nucleotide-based drug consisting of cytidinemonophosphate, uridinemonophosphate, uridin-ediphosphate and uridinetriphosphate.
0 kommentar(er)
